## Study design LUMEN-1 (EORTC 2334)

**Recurrent meningioma** WHO grade 1, 2, 3 No local therapy indicated No prior systemic therapy Measurable disease Radiologically documented progression (>25% in last 2 y) SSTR-positive (confirmed by PET)



177Lu-DOTATATE (7.4 GBq i.v. every 4 weeks, 4 cycles)

**Local standard of care (LOC)** 

- **136** patients
- **35** sites
- **10** countries

## Stratification:

- Country
- WHO grade 1 vs 2/3
- Age ( $\leq$ , > 60)
- Performance status (0, >0)
- Size (≤, >43 mm)

- Primary endpoint: Progression-free survival (RANO meningioma criteria)
- Secondary endpoints: Response rate, OS, safety, HRQoL, neurological function
- Exploratory analyses: validation of tissue-based factors (methylation, genetic profiling), prognostic and predictive value of SSTR-PET, validation of PET-based response criteria, correlation of dosimetry with outcome, investigation of 3D volumetry